iHealthScreen Developed and Validated Risk Prediction Models for Cardiovascular Diseases Using Individual’s Retinal Color Images and Health Data
May 24 2024 - 3:16PM
Business Wire
The stroke and heart attack prediction
results will be presented at the 47th Congress of the European
Society of Cardiology (ESC), London, UK, from 30th August to 2nd
September 2024.
iPredict™ Stroke and heart attack prediction models provide
AI-based automated prediction scores for incident stroke and heart
attack (i.e., myocardial infarction (MI)) which identifies
the individuals who are at risk of having stroke and MI within 5
years. These results were peer-reviewed and accepted by the
scientific review team and will be presented at the ESC Congress
which will be held between 30th August and 2nd September 2024. The
iPredict stroke and MI prediction models aim to help prevent
strokes and heart attacks, saving millions of people from deaths or
disabilities.
Using the high-resolution retinal color images of the
individual’s eyes and health data, the iPredict™ AI System’s stroke
and MI prediction results will be available in fully automated
reports in less than 60 seconds. The entire test can easily and
reliably be completed within 5 minutes.
For the identification of individuals who will suffer a stroke
or heart attack in 5-year, the prediction models offer an overall
accuracy of
- incident stroke with a sensitivity of 82.73%, specificity of
87.35%, and accuracy of 85.22%.
- incident MI with a sensitivity of 84.76%, specificity of
84.67%, and accuracy of 84.71%.
iPredict achieved higher accuracy than existing stroke and heart
attack prediction models such as Framingham and Chads
scores/CHADS2VASC scores.
iPredict’s stroke and MI models can be used to alert physicians
of the need to take further preventive measures for these patients
in the primary care settings.
The company also has AI-based screening tools for early
diagnosis of diabetic retinopathy (DR), age-related macular
degeneration (AMD), and glaucoma which are CE certified (i.e.,
cleared for the European market), MHRA/UK Health, TGA/Australian
and UAE health approved.
iHealthScreen company is open to partnerships for collaboration
and/or co-development of its products in various territories. For
more information: https://www.iHealthScreen.org
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240524779966/en/
Alauddin Bhuiyan, Ph.D. CEO, iHealthScreen Inc. E:
bhuiyan@ihealthscreen.org T: +1 718 926 9000